Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Journal of Hematology and Oncology Année : 2012

Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.

Résumé

ABSTRACT: The ASXL1 gene is one of the most frequently mutated genes in malignant myeloid diseases. The ASXL1 protein belongs to protein complexes involved in the epigenetic regulation of gene expression. ASXL1 mutations are found in myeloproliferative neoplasms (MPN), myelodysplastic syndromes (MDS), chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML). They are generally associated with signs of aggressiveness and poor clinical outcome. Because of this, a systematic determination of ASXL1 mutational status in myeloid malignancies should help in prognosis assessment.

Domaines

Cancer Hématologie
Fichier principal
Vignette du fichier
1756-8722-5-12.pdf (259.23 Ko) Télécharger le fichier
1756-8722-5-12.xml (76.51 Ko) Télécharger le fichier
Origine : Fichiers éditeurs autorisés sur une archive ouverte
Format : Autre
Loading...

Dates et versions

inserm-00698796 , version 1 (17-05-2012)

Identifiants

Citer

Véronique Gelsi-Boyer, Mandy Brecqueville, Raynier Devillier, Anne Murati, Marie-Joelle Mozziconacci, et al.. Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases.. Journal of Hematology and Oncology, 2012, 5 (1), pp.12. ⟨10.1186/1756-8722-5-12⟩. ⟨inserm-00698796⟩
139 Consultations
220 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More